Acute hemarthroses: The benefits of early versus late treatment with recombinant activated factor VII

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 4 SUPPL. 1, 2000, Pages

  Lusher, J M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Acute hemarthroses; Home treatment; Inhibitors; Recombinant factor VIIa; rFVIIa; Target joints

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034129960     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200004001-00010     Document Type: Conference Paper

References (9)

1. Lusher JM. Recombinant factor VIIa (NovoSeven®) for treatment of intramuscular hemorrhages - a comparison of early versus late treatment Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 111-114.
2. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
3. Hedner J, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
4. Molskøv Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 (suppl 1): 135-138.
5. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, et al. A randomized double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B with and without inhibitors. Haemophilia 1998; 4: 790-798.
6. Key NS, on behalf of the U.S. rFVIIa Home Therapy Study Group. Efficacy of recombinant activated Factor VII when administered in the home to control joint, muscle, and mucocutaneous bloods in hemophilia patients with inhibitors. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 153.
7. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant Factor VIIa (NovoSeven®) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
8. Laurian Y, Goudemand J, Negrier C, Vicariot M, Marqués-Verdier A, Fonlupt J, et al. Use of recombinant, activated factor VII as first-line therapy for bleeding episodes in hemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 9 (suppl 1): 155-156.
9. Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol Suppl 1998; 63: 11-14.